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Abstract 
Chronic stress can now be physiologically traced as a significant player in the creation of osteoporotic bones.  
The present pilot study involved 100 women, (N:42 have been diagnosed with osteopenia, N:21have been 
diagnosed with osteoporosis, N:37 had a non-osteoporotic condition), who participated in the Hellenic Society of 
Osteoporosis Association Support. Correlations between somatic symptoms of anxiety and osteoporosis, and 
among medications and anxiety symptoms in menopausal women were explored. Assessments were based on a 
self-report demographic questionnaire and on the Short Anxiety Screening Test (SAST) administered for 
detection of anxiety disorder and somatization. Statistical analysis detected non-significant differences regarding 
the correlation between anxiety symptomatology or somatization due to osteoporosis and osteopenia diagnosis. 
The same pattern is observed among women’s age group, the occupational and marital status. Hypothesis that the 
osteoporosis and osteopenia group would manifest significant relationships with age group and medicines was 
comfirmed, as well as between somatization and medicines women with osteoporosis and osteopenia undertake. 
The results suggest that women are not prone to manifest anxiety or somatization in relation to the osteoporosis 
condition. However, the majority of women with osteoporosis and osteopenia consume more than two medicines 
other than those for osteoporosis. This quantity and combination they undertake appear to contribute and 
deteriorate their anxiety/somatization symptomatology. Further research based on a larger sample would give us 
more definite results. 
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1. Introduction 
     A high stress lifestyle has always been suspected as one of the contributing causes of osteoporosis and other 
major health problems. According to Kumano (2005), there may be three ways of relationship between stress and 
osteoporosis. The first is that stress induces some physiological changes leading to osteoporosis. The second is 
that stress induces behavioral distortion of eating, drinking, exercise, and sleep habits, which leads to 
osteoporosis. The third is that osteoporosis, on the other hand, brings about anxiety, depression, loss of social 
roles, and social isolation, which leads to stress. Postmenopausal and young women form the susceptible sex and 
age groups. 
     But what is really happening inside the body as a result of high stress living and how does it affect bones? 
Constant stress promotes an unhealthy hormone shift increasing cortisol and reducing serotonin levels. Higher 
cortisol levels increase total body inflammation decreasing calcium absorption and increased calcium excretion. 
Osteoblasts (bone-building cells) are reduced in number impairing the bones ability to renew which is essential to 
maintaining normal bone density. Stress causes less bone to be created and more bone to be destroyed resulting in 
osteoporosis. There are two types of stress responses in our lives, a short term response and a long term 
response.  The short term response is considered to be governed by the sympathetic nervous system.  The long 
term response characteristically involves the release of glucocorticoids, namely cortisol (Baek et al, 2010). The 
role of stress is described in the work of Chiodini and his colleagues (Chiodini et al, 2008). Based on their study, 
cortisol excess inhibits bone formation, increases bone resorption, impairs calcium absorption from the gut, and 
affects the secretion of several hormones (in particular gonadotropins and GH), cytokines, and growth factors, 
influencing bone metabolism. The authors note as well that, subclinical hypercortisolism, a condition of impaired 
hypothalamic-adrenal axis homeostasis without the classical signs and symptoms of glucocorticoid excess, is a 
recently defined entity, which has been shown to be associated to increased bone resorption, bone loss, and high 
prevalence of vertebral fractures regardless of gonadal status (Chiodini et al, 2008). 
      Thus, negative emotions, such as depression or anxiety, can directly affect the cells of the immune system 
and either up- or down-regulate the secretion of proinflammatory cytokines. In addition, negative emotions may 
also contribute to prolonged or chronic infections or to delayed wound healing, processes that indirectly fuel 
proinflammatory cytokine production. These changes are likely to be greatest and to carry the highest health 
risks, among the elderly, who already show age-related increases in IL-6 production (H. J. Cohen, 2000). Indeed, 
inflammation has recently been linked to a spectrum of conditions associated with aging, including 
cardiovascular disease, osteoporosis, arthritis, Type 2 diabetes, certain lymphoproliferative diseases or cancers 
(including multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia), Alzheimer’s 
disease, and periodontal disease (Ershler & Keller, 2000). Chronic inflammation has been suggested as one key 
biological mechanism that may fuel declines in physical function, leading to frailty, disability, and, ultimately, 
death (Cohen, Pieper, Harris, Rao, & Currie, 1997; Hamerman, 1999; Taaffe, Harris, Ferrucci, Rowe & Seeman, 
2000). 
      This should bear in mind as individuals and especially the female gender consider a number of ways to  
maintain good bone health and prevent osteoporosis. For this reason effective treatment programs for healthy 
bones must include mechanisms to prevent the negative effects of stress on woman’s body. Reducing the 
negative effects of stress on the body will help the cells responsible for healthy bones begin to function normally 
again. In a nutshell, the time spent promoting good mental wellbeing is as important as caring for good physical 
health.  
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      The present study aims at shedding light, and exploring the links and correlations that can be established 
between somatization and osteoporosis in women. Our hypothesis is that anxiety precipitates osteoporosis in 
some women, which acts as a predisposing factor for osteoporosis. This means that those with diagnosed 
osteoporosis might have a high likelihood of manifesting somatic symptoms of anxiety. Specifically, they have a 
difficulty controlling their anxiety because of their osteoporosis as well. What is more, we investigate the extent 
to which the usage of a variety of medications can have a considerable effect on the positive symptomatology of 
somatized anxiety. 
2.  Method  
2.1. Participants characteristics 
    The study group was a total of 100 women, who were involved in the actions of the Hellenic Society of 
Osteoporosis Association Support, a non-profit organization, officially recognized by the International 
Osteoporosis Foundation (IOF) and the World Health Organization (WHO). The participants of our study were 
assigned to three distinct categories according to their osteoporotic diagnosis. The first group was women with 
osteoporosis (N=21), the second women with osteopenia (N=42) and the third women with a non-osteoporotic 
condition (N=37). The mean age of women was 56 years (range 18-80, std: 12.47). Based on women’s age and 
their osteoporosis condition three age categories were formed as well: women belonging to age group 18-44, 45-
54 and 55-80 respectively. Women indicated their marital and occupational designations. The majority of women 
were married (67%) and employed (57%), followed by categories of unemployed (43%), single (18%), widowed 
(9%) and divorced women participants (6%).  
2.2  Psychometric Instruments 
     Demographic Information Sheet. A Demographic Information Sheet was used in eliciting demographic and 
situational information including: women’s age, their marital and employment status, their current health in 
relation to the osteoporotic diagnosis and the consumption of a series of medications prescribed to them apart 
from osteoporotic ones. These medications were prescribed for heart, pressure or cholesterol symptomatology, 
diabetes, respiratory or asthma conditions, gastrointestinal complaints, thyroid dysregulation and psychiatric 
indications. 
     Short Anxiety Screening Test. The Short Anxiety Screening Test (SAST) was developed to provide clinicians 
with a simple tool for detecting anxiety disorders in older people. It was developed and standardised in  by Sinoff 
et al (1999) and was considered appropriate for our study purpose for the following reasons: it is short and easy 
to apply in clinical settings and it is based on an interviewer-assisted self-rating scale which was developed to 
standardize the detection of anxiety disorder, rendering it practical for use in everyday practice. According to the 
developers, the instrument can accurately and reliably identify symptoms of anxiety in older people even, and 
especially, in the presence of depression. The scale is comprised of 10 items including somatic complaints, often 
the manifestation of anxiety in the older population (Sinoff, Ore, Zlotogorsky & Tamir, 1999).  
      SAST fulfils the criteria defined by the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV) and contains questions relating to somatic symptoms, often the manifestation of anxiety (American 
Psychiatric Association, 2000). Indicative questions are the following: “Do you feel keyed up, on edge?”, “Do 
you feel that something terrible is going to happen?”, “Are you worrying about your present state?”, “Do you feel 
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you have control of your life?”, “Can you relax?”, “Do you suffer from back pain, neck pain and headache?”, 
“Do you sweat a lot or suffer from palitations?”, “Have you been irritable?”, “Do you sleep well?”, “Do you 
suffer from dizziness of faintness?” The scale consists of 10 items rated on a 4-point response scale, ranging from 
1 (rarely or never), 2 (sometimes), 3 (often) to 4 (always), and generating scores between 10 and 40, with a 
higher score equalling a higher degree of anxiety. SAST requires 10 to 15 min to administer and a total score is 
calculated by the sum of the grades of all questions. A score of ≥ 24 is the cut-off point for the diagnosis of 
anxiety, while a score of 22 to 23 reflecting borderline test results (Grammatikopoulos et al, 2010).  
    Our research study was based on the Greek version of the Short Anxiety Screening Test (SAST). This 
adaptation of the SAST questionnaire is comparable with that of the original version in terms of reliability and 
can be used in primary healthcare research settings. The psychometric properties of the Greek version of the 
SAST scale in primary care were good. Internal consistency of the instrument was good, the Cronbach α was 
found to be 0.763 (P < 0.001) and ICC (95% CI) for reproducibility was found to be 0.763 (0.686 to 0.827). 
Factor analysis revealed three factors with eigenvalues >1.0 accounting for 60% of variance, while the Cronbach 
α was >0.7 for every item. Its use in clinical practice should be primarily administered as a screening tool only at 
this stage, with a follow-up consisting of a detailed interview with the patient, in order to confirm the diagnosis 
(Grammatikopoulos et al, 2010).  
       
2.3 Statistical Analysis 
      All statistical analyses were performed using the Stattistical Package for Social Sciences (SPSS version 
20.0). The social-demographical characteristics of the sample were summarized using descriptive statistics.  Chi-
square test (x2) was used to examine differences with categorical variables for estimating how closely an 
observed distribution matches an expected distribution and whether two random variables are independent or not. 
Analysis of variance (ANOVA) procedures were implemented with Bonferroni corrections, since our study 
involved three levels of the osteoporotic status as the independent variable that examined the differences between 
group means and variation among and between groups.  
3. Results  
      The first hypothesis, that the osteopenia and osteoporosis group would exhibit significantly higher 
proportions of somatised anxiety in comparison to the non-osteoporotic women was not supported. This means 
that osteoporotic women and women with osteopenia do not differ from the non-osteoporotic across the 
dimensions of anxiety. In other words, women with an osteoporotic and osteopenia diagnosis do not present a 
vulnerability to express somatic symptoms of anxiety in contrast with the undiagnosed women (Table 1). The 
same finding was observed among their age group, the occupational and marital status.  
     However, the hypothesis examining the relationship between medicines, osteoporosis somatization and age 
group was affirmed, by giving statistically significant relationships (Table 1). More specifically, women who 
belonged to the older age group, ranging from 55-80, had been diagnosed with osteopenia and osteoporosis. 
Therefore, the older a woman is the higher is the possibility of gaining an osteoporotic diagnosis [x2 (4, N = 100) 
= 16.77, p<.01)]. Thus, prescription and consumption of medications in this age group is a common phenomenon. 
Significant causative relationships were discovered among the osteoporosis and medications [x2(4, N=100)= 
11.18, p<0.05) and between somatization of anxiety and medications women undertake [x2 (2, Ν=100) = 8.54, 
p<0.01)]. 
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Table 1. Relationships between somatization, medicines and osteoporosis 
Abbreviations: NS: non significant  
                         *p< .05  
                       **p< .0.1  
                     ***p< .001  
 
Table 2. Analysis of Variance for Severity of sleep disturbance and dizziness/faintness symptoms as a result of medicines      
       Abbreviations: NS: non significant,  
                                SS: sum of squares 
                                MS: mean squares 
                              
*p< .05 
 
                   **p< .0.1  
                ***p< .001  
      
    These findings lead to the assumption that the quantity and the combination of medicines osteoporotic women 
consume deteriorate their anxiety symptomatology compared with the non-osteoporotic group. What is more, 
women with osteopenia and osteoporosis tend to consume a variety of medications (more than two) for other 
health problems apart from osteoporosis unlike the non-osteoporotic women. The main effect of medicines on 
sleep pattern or severity of sleep disturbance [F(2,97)=4.749, p<.01)] and dizziness/faintness indications 
[F(2,97)=6.308), p<.01)] were found to be significant among the osteopenia and osteoporosis group (Table 2). 
This outcome proposes that women belonging to the older age group (55-80 years of age) who tend to consume 
  
Categorical 
variables 
Women with 
Osteoporosis 
(N=21) 
(%) 
Women with 
Osteopenia 
(N=42) 
(%) 
Non-osteoporotic     
women 
(N=37) 
(%) 
 
Total (%) 
 
x2 (P-value) 
Age group 18-44 0 3 11 14 16.77(.002)** 
45-54 2 9 9 20 
55-80 19 30 17 66 
Medicines Nothing 2 10 17 29     11.18 (.025)* 
1 8 17 7 32 
More than 2 11 15 13 39 
SAST Result Positive 7 16 11 34 .619 NS 
Negative 14 26 26 66 
Source of variance SS df MS F p 
Severity of sleep disturbance 
 
 
Between-subjects effects 
 
Within-subjects effects 
 
 
 
 
 
          10.926 
 
111.584 
 
 
 
              2 
 
97 
 
 
 
              5.46 
 
1.150 
 
 
 
 
 
4.319 
 
.685 
 
 
 
 
          4.75 
 
 
 
 
 
 
            .011** 
Dizziness/Faintness 
Symptoms 
 
Between-subjects effects 
 
Within-subjects effects 
 
 
 
 
 
8.637 
 
66.403 
 
 
 
2 
 
97 
 
 
 
 
6.308 
 
 
 
 
0.03* 
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more than two medicines have higher degrees of somatized anxiety symptoms as a causal effect and attribute of 
their medications.   
4. Discussion 
      Somatization is generally defined as the tendency to express emotional dysphoria with physical signs 
(Spinhoven & van der Does, 1997). In somatisation, psychosocial or emotional problems are expressed with 
physical signs, such signs are attributed to a physical disease, and medical assistance is sought (Ford, 1986). 
While no consensus has been reached on its definition and classification, the common expression used for 
somatization is the presence of physical complaints that cannot be explained by a somatic disease (Ford, 1986). 
Somatization is primarily the wide scoped clinical phenomenon of the somatic signs that are defined with mental 
processes instead of structural or somatic disorders. While somatization may also be a temporary complaint or 
primary symptom of many psychological diseases, it may also be a somatic stress expression influenced by 
culture and social life as a way of learned behavior, an exaggerated manner of discourse of an organic disorder, 
the use of certain medications that induce somatized-anxiety like symptoms  or a representation of some personal 
characteristics (Kirmayer &Young, 1998; Bitzer, 2003). 
    Our study revealed that women are not prone to manifest anxiety or somatization in relation to the osteoporosis 
condition. However, the majority of those with osteoporosis and osteopenia consume more than 2 medicines 
other than osteoporosis. As a consequence, the potent interaction and interplay that medicines inflict on the 
biopsychological organism worsen the somatisation process. Specifically, questions of the Short Anxiety 
Screening Test (SAST) that examined sleep patterns (“Do you sleep well?”) and dizziness/faintness (“Do you 
suffer from dizziness/faintness”) constructed statistical significant relationships with the medications as the 
dependent variables for their impact on the anxiety symptomatology. 
      The above results can be interpreted from the perspective of viewing the sympathetic nervous system, as the 
fight or flight mechanism of the human body that plays a crucial role in this process. Drugs that may trigger 
anxiety symptoms will often affect the sympathetic nervous system. This large group of drugs are called 
sympathomimetics that include alpha-1 agonists, such as phenylephrine contained in nasal decongestants, or beta 
agonists, such as albuterol contained in inhalers that are used in asthma. In addition to the sympathomimetics, 
other drug classes may give rise to anxiety symptoms. These include corticosteroids that may be used orally or 
intravenously in conditions such as asthma or multiple sclerosis, as well as other drugs, such as thyroid 
hormones. In addition to these major classes of drugs that cause anxiety symptoms, other drugs such as 
anticholinergic agents, anticonvulsants, antihistamines, insulin, oral contraceptives, antihypersensitive and 
cardiovascular medications, antidepressant, anxiolytic pharmacotherapy may also give rise to anxiety (Cates et al. 
1996; Kirkwood & Melton, 2002; Augustin, 2005). Women who participated in the study recognized and 
identified the consumption of the above major classes of drugs, which they had a direct impact in their tendency 
to somatise.  
 
5. Strengths and limitations 
       The findings from this study approach the subject within a biomedical paradigm, but within this paradigm 
explores how women’s anxiety symptomatology is exacerbated by the range of medicines they take. There 
appears to be an argument around the over-medicalisation effect on women’s psychological well-being. Even 
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though, the study highlights the causal relationship between medicines and somatization, there are some 
limitations that warrant discussion.  
       Initially, our sample consisted of 100 women who were active members of the Hellenic Society of 
Osteoporosis Association Support. This means that the participants were selected from a specific target group by 
excluding osteoporotic women who were not participants of the Association. Another fact is that other 
psychosocial factors, such as psychiatric history, physical illness and social support should be considered in our 
future study, as they might interfere with the relationship between anxiety and medications. Further research with 
bigger and random sample is required in order to clarify and generalize through representativeness our results. 
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